These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?
https://www.fool.com/investing/2023/12/18/these-are-the-3-hottest-biopharma-trends-of-2024/?source=iedfolrf0000001
Dec 18, 2023 - 2024 is going to be a sizzler in the biopharma sector.
0
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
https://www.fool.com/investing/2023/12/21/weighing-their-chances-5-leading-healthcare-compan/?source=iedfolrf0000001
Dec 21, 2023 - Which weight-loss stocks are good buys today?
0
AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/02/08/astrazeneca-plc-azn-q4-2023-earnings-call-transcri/?source=iedfolrf0000001
Feb 08, 2024 - AZN earnings call for the period ending December 31, 2023.
0
4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
https://www.fool.com/investing/2024/04/14/nasdaq-bull-market-4-growth-stocks-regret-not-buy/?source=iedfolrf0000001
Apr 14, 2024 - Amazing deals can still be found by opportunistic investors, even with the Nasdaq Composite reaching new heights.
0
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/04/25/astrazeneca-plc-azn-q1-2024-earnings-call-transcri/?source=iedfolrf0000001
Apr 25, 2024 - AZN earnings call for the period ending March 31, 2024.
0
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
https://www.fool.com/investing/2024/03/28/bull-market-buys-3-dividend-stocks-to-own-for-the/?source=iedfolrf0000001
Mar 28, 2024 - Invest in stability, dividends, and growth with these three accomplished real estate operators.
0
AstraZeneca (AZN) to Discontinue Two Studies on Lokelma
https://www.zacks.com/stock/news/2192314/astrazeneca-azn-to-discontinue-two-studies-on-lokelma?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2192314
Dec 01, 2023 - Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.
0
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
https://www.zacks.com/stock/news/2193151/lilly-lly-gets-second-fda-nod-for-lymphoma-drug-jaypirca?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193151
Dec 04, 2023 - Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
0
Novartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug
https://www.zacks.com/stock/news/2194094/novartis-nvs-gets-fda-nod-for-rare-blood-disorder-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2194094
Dec 06, 2023 - Novartis (NVS) obtains FDA approval for Fabhalta, the first oral monotherapy for treating adults with PNH.
0
Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus
https://www.zacks.com/stock/news/2195113/sanofi-sny-posts-upbeat-long-term-outlook-enhances-r-d-focus?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195113
Dec 07, 2023 - Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.
0
Page 1>